bioRxivCancer Biology
PIM Kinases Alter Mitochondrial Dynamics and Chemosensitivity in Lung Cancer
S. S. Chauhan, R. K. Toth, C. C. Jensen, A. L. Casillas, D. S. Kashatus, N. A. Warfel
Abstract
Resistance to chemotherapy represents a major obstacle to the successful treatment of non-small cell lung cancer (NSCLC). The goal of this study was to determine how PIM kinases impact mitochondrial dynamics, ROS production, and response to chemotherapy in lung cancer. Live cell imaging and microscopy were used to determine the effect of PIM loss or inhibition on mitochondrial phenotype and ROS. Inhibition of PIM kinases caused excessive mitochondrial fission and significant upregulation of mitochondrial superoxide, increasing intercellular ROS. Mechanistically, we define a signaling axis linking PIM1 to Drp1 and mitochondrial fission in lung cancer. PIM inhibition significantly increased the protein levels and mitochondrial localization of Drp1, causing marked fragmentation of mitochondria. An inverse correlation between PIM1 and Drp1 was confirmed in NSCLC patient samples. Inhibition of PIM sensitized NSCLC to chemotherapy and produced a synergistic anti-tumor response in vitro and in vivo. Immunohistochemistry and transmission electron microscopy verified that PIM inhibitors promote mitochondrial fission and apoptosis in vivo. These data improve our knowledge about how PIM1 regulates mitochondria and provide justification for combining PIM inhibition with chemotherapy in NSCLC.
- organism: human
- assay: proteomics
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response
R. Cuttano, T. Colangelo, … F. Bianchi·Journal of Hematology & OncologyPeer-reviewed·Dec 31, 2022
- Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2
- Depletion of chemoresponsive mitochondrial fission mediator DRP1 does not mitigate sarcoma resistance
Karolina Borankova, Matyas Solny, … Jan Skoda·Life Science AlliancePeer-reviewed·Dec 6, 2024
- Close homologue of L1 sensitizes lung cancer cells to cisplatin and paclitaxel via inhibition Akt pathway
- Concurrent PIK3CA mutant drives cachexia through inflammatory signaling in EGFR mutant lung cancer
Meiting Yue, Zhen Qin, … Hongbin Ji·bioRxiv·Jan 17, 2025
- MYC plus class IIa HDAC inhibition potentiates mitochondrial dysfunction in non-small cell lung cancer
Jina Park, Ying-Yu Chen, … Michael J. Topper·Cell ReportsPeer-reviewed·May 19, 2025